Observational Evaluation of Atopic Dermatitis in Pediatric Patients

Pediatric Atopic Dermatitis and Treatment Patterns

Recruiting
11 years or below
All
Phase N/A
1845 participants needed
6 Locations

Study Overview

Primary Objectives:

  • To describe the characteristics of pediatric patients with moderate to severe atopic dermatitis (AD) whose disease is not adequately controlled with topical therapies or when those therapies are not medically advisable.
  • To evaluate the time-course of AD and selected atopic comorbidities.

Secondary Objectives:

  • To characterize disease burden and unmet need.
  • To describe real-world treatment patterns (eg, dosing regimens, treatment duration, and reasons for discontinuation and/or switching).
  • To document the real-world effectiveness and safety of treatments.

Study Details

The study duration is 120 months.

Eligibility Criteria

You may be eligible for this study if you meet the following criteria:

  • Conditions: Dermatitis Atopic
  • Age: 11 years or below
  • Gender: All

Inclusion criteria:

  • Patients with moderate to severe AD, according to the Investigator's assessment;
  • Currently receiving systemic treatment (including phototherapy) for atopic dermatitis or currently on topical treatment, but otherwise candidates for systemic treatment.

Exclusion criteria:

  • Concurrent participation in an interventional clinical trial which modifies patient care.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Updated on 24 Apr 2025. Study ID: NCT03687359

This study investigates pediatric patients with moderate to severe atopic dermatitis (AD), a skin condition causing red, itchy, and inflamed skin. The purpose is to understand the characteristics of these patients, especially when their condition is not well-managed with topical treatments, or when such treatments are not suitable.

Participants will be observed to evaluate the progression of atopic dermatitis and related conditions. The study will also look into the burden of the disease, treatment patterns, and the safety and effectiveness of real-world treatments.

  • Who can participate: Children with moderate to severe atopic dermatitis receiving systemic treatment, or candidates for it, can participate. They should not be involved in another clinical trial that changes their treatment.
  • Study details: Participants will continue their current treatments, which may include systemic therapies or phototherapy. The study will observe their treatment patterns and document the effectiveness and safety of these treatments.
  • Study Timelines: The study will last 120 months.

Find a Study Location to Connect

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language